Novo Nordisk A/ S stock (DK0062498333): Valuation focus after Deutsche Bank reiteration

Novo Nordisk A/S is in focus on Nasdaq Copenhagen after Deutsche Bank reiterated its Neutral view on 05/29/2026, keeping valuation in the spotlight for Danish investors.

Novo Nordisk A/S is drawing attention on Nasdaq Copenhagen after Deutsche Bank reiterated its Neutral rating at 07:35am ZD on 05/29/2026, according to Marketscreener. The latest note keeps the Danish drugmaker in the valuation debate at home, where the shares trade under ISIN DK0062498333 on Nasdaq Copenhagen.

The stock traded at 44.55 USD on 05/27/2026 on the U.S. market for the ADR line, according to Investing.com. In Germany, the stock traded via Tradegate at 44.55 EUR on 05/27/2026.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Novo Nordisk
• Sector/industry: Pharmaceuticals
• Headquarters/country: Bagsvaerd, Denmark
• Core markets: Denmark, the United States, Europe, and other international markets
• Key revenue drivers: Diabetes and obesity treatments, including GLP-1 medicines
• Home exchange/listing venue: Nasdaq Copenhagen (NOVO B)
• Trading currency: DKK

Novo Nordisk A/S: core business model

The company develops and sells prescription medicines, with its commercial profile still anchored by diabetes care and weight-management therapies.

Valuation metrics and multiples for Novo Nordisk A/S

MarketScreener’s quote page for Novo Nordisk A/S lists the latest news item on 05/29/2026 and identifies the shares on Nasdaq Copenhagen under NOVO B, reinforcing the home-market angle for Danish investors. The same source also showed Deutsche Bank reiterating a Neutral rating on 05/29/2026, a reminder that valuation remains a live theme even without a fresh earnings release.

For readers tracking the German-accessible line, the ADR reference price of 44.55 USD on 05/27/2026 gives a cross-market snapshot, but it should not be confused with the Copenhagen listing. Investors following the Danish line can compare the home-market quote with the ADR move to gauge whether sentiment is being driven by U.S. trading or by developments tied more closely to the primary listing.

Conclusion

Deutsche Bank's Neutral call leaves the Danish pharma group in a valuation-led discussion rather than a catalyst-led one. With Nasdaq Copenhagen still the anchor and the ADR line offering a separate trading read, the next market focus is likely to stay on whether fresh company data can change the debate.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.